- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Valiant Laboratories Limited — Board Meeting, 11-02-2026: Outcome of Board Meeting
11-02-2026 | 04:51 pm
11-02-2026 | 04:51 pm
Valiant Laboratories' board has approved its Q3 FY26 consolidated financial results. Revenue from operations stood at ₹5.25 Cr, while the company reported a net loss of ₹7.06 Cr. EPS was ₹(1.30).
No comments yet. Be the first to comment!